Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Livio Pagano, Francesco Passamonti, Chiara Cattaneo, Luca Arcaini, Riccardo Bruna, Michele Cavo, Francesco Merli, Emanuele Angelucci, Mauro Krampera, Roberto Cairoli, Matteo Giovanni Della Porta, Nicola Fracchiolla, Marco Ladetto, Carlo Gambacorti Passerini, Marco Salvini, Monia Marchetti, Roberto Lemoli, Alfredo Molteni, Alessandro Busca, Antonio CuneoAlessandra Romano, Nicola Giuliani, Sara Galimberti, Alessandro Corso, Alessandro Morotti, Brunangelo Falini, Atto Billio, Filippo Gherlinzoni, Giuseppe Visani, Maria Chiara Tisi, Agostino Tafuri, Patrizia Tosi, Francesco Lanza, Massimo Massaia, Mauro Turrini, Felicetto Ferrara, Carmela Gurrieri, Daniele Vallisa, Maurizio Martelli, Enrico Derenzini, Attilio Guarini, Annarita Conconi, Annarosa Cuccaro, Laura Cudillo, Domenico Russo, Fabrizio Ciambelli, Anna Maria Scattolin, Mario Luppi, Carmine Selleri, Elettra Ortu La Barbera, Celestino Ferrandina, Nicola Di Renzo, Attilio Olivieri, Monica Bocchia, Massimo Gentile, Francesco Marchesi, Pellegrino Musto, Augusto Bramante Federici, Anna Candoni, Adriano Venditti, Carmen Fava, Antonio Pinto, Piero Galieni, Luigi Rigacci, Daniele Armiento, Fabrizio Pane, Margherita Oberti, Patrizia Zappasodi, Carlo Visco, Matteo Franchi, Paolo Antonio Grossi, Lorenza Bertù, Giovanni Corrao, Paolo Corradini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

49 Citazioni (Scopus)

Abstract

Background: Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance on COVID-19 aimed to collect data from adult patients with haematological malignancies who required hospitalisation for COVID-19. Methods: This multicentre, retrospective, cohort study included adult patients (aged ≥18 years) with diagnosis of a WHO-defined haematological malignancy admitted to 66 Italian hospitals between Feb 25 and May 18, 2020, with laboratory-confirmed and symptomatic COVID-19. Data cutoff for this analysis was June 22, 2020. The primary outcome was mortality and evaluation of potential predictive parameters of mortality. We calculated standardised mortality ratios between observed death in the study cohort and expected death by applying stratum-specific mortality rates of the Italian population with COVID-19 and an Italian cohort of 31 993 patients with haematological malignancies without COVID-19 (data up to March 1, 2019). Multivariable Cox proportional hazards model was used to identify factors associated with overall survival. This study is registered with ClinicalTrials.gov, NCT04352556, and the prospective part of the study is ongoing. Findings: We enrolled 536 patients with a median follow-up of 20 days (IQR 10-34) at data cutoff, 85 (16%) of whom were managed as outpatients. 440 (98%) of 451 hospitalised patients completed their hospital course (were either discharged alive or died). 198 (37%) of 536 patients died. When compared with the general Italian population with COVID-19, the standardised mortality ratio was 2·04 (95% CI 1·77-2·34) in our whole study cohort and 3·72 (2·86-4·64) in individuals younger than 70 years. When compared with the non-COVID-19 cohort with haematological malignancies, the standardised mortality ratio was 41·3 (38·1-44·9). Older age (hazard ratio 1·03, 95% CI 1·01-1·05); progressive disease status (2·10, 1·41-3·12); diagnosis of acute myeloid leukaemia (3·49, 1·56-7·81), indolent non-Hodgin lymphoma (2·19, 1·07-4·48), aggressive non-Hodgkin lymphoma (2·56, 1·34-4·89), or plasma cell neoplasms (2·48, 1·31-4·69), and severe or critical COVID-19 (4·08, 2·73-6·09) were associated with worse overall survival. Interpretation: This study adds to the evidence that patients with haematological malignancies have worse outcomes than both the general population with COVID-19 and patients with haematological malignancies without COVID-19. The high mortality among patients with haematological malignancies hospitalised with COVID-19 highlights the need for aggressive infection prevention strategies, at least until effective vaccination or treatment strategies are available.
Lingua originaleEnglish
pagine (da-a)e737-e745
Numero di pagine8
RivistaTHE LANCET. HAEMATOLOGY
Volume7
DOI
Stato di pubblicazionePubblicato - 2020

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Betacoronavirus
  • COVID-19
  • Comorbidity
  • Coronavirus Infections
  • Female
  • Follow-Up Studies
  • Hematologic Neoplasms
  • Humans
  • Inpatients
  • Italy
  • Leukemia
  • Lymphoma, Non-Hodgkin
  • Male
  • Middle Aged
  • Myeloproliferative Disorders
  • Neoplasms, Plasma Cell
  • Pandemics
  • Pneumonia, Viral
  • Retrospective Studies
  • Risk Factors
  • SARS-CoV-2
  • Young Adult

Fingerprint Entra nei temi di ricerca di 'Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study'. Insieme formano una fingerprint unica.

Cita questo